Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d):the carmelina randomised controlled trial

Wanner, Christoph, Cooper, Mark E., Johansen, Odd Erik, Toto, Robert, Rosenstock, Julio, McGuire, Darren K., Kahn, Steven E., Pfarr, Egon, Schnaidt, Sven, von Eynatten, Maximilian, George, Jyothis T., Gollop, Nicholas D., Marx, Nikolaus, Alexander, John H., Zinman, Bernard, Perkovic, Vlado and , CARMELINA Invest (2021) Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d):the carmelina randomised controlled trial. Clinical Kidney Journal, 14 (9). p. 2136. ISSN 2048-8505

Full text not available from this repository. (Request a copy)

Abstract

This is a correction to: Clinical Kidney Journal, Volume 14, Issue 1, January 2021, Pages 226–236, https://doi.org/10.1093/ckj/sfaa225 In the originally published version of this manuscript, the legend for Figure 4 incorrectly directed the reader to the right side of the curve, this has been corrected to read: ‘Point estimates on the left side of the curve indicate a positive effect for LINA.’

Item Type: Article
Uncontrolled Keywords: sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: LivePure Connector
Date Deposited: 20 Dec 2021 12:30
Last Modified: 18 Jan 2022 17:30
URI: https://ueaeprints.uea.ac.uk/id/eprint/82737
DOI: 10.1093/ckj/sfab104

Actions (login required)

View Item View Item